S-1/A: Salarius Pharmaceuticals Updates S-1 Filing, Details Merger with Decoy Therapeutics

Salarius Pharmaceuticals files an amendment to its S-1 registration statement, updating business and financial information related to its merger with Decoy Therapeutics and responding to SEC comments.

Summary

• Salarius Pharmaceuticals has updated its S-1 filing with the SEC, providing new business and financial details.
• The update relates to the proposed merger with Decoy Therapeutics, a pre-clinical stage biotechnology company.
• The merger is structured as a stock-for-stock transaction, with Decoy stockholders expected to own approximately 85.9% of the combined company.
• The merger is contingent upon a minimum of $6.0 million in financing and continued listing on Nasdaq.
• Salarius intends to commence the Nasdaq initial listing process prior to the consummation of this offering and the Merger Closing.
• The combined company will focus on developing innovative peptide conjugates, leveraging Decoy's IMP 3 ACT platform and Salarius' SP-3164 compound.
• Salarius has received a delisting notice from Nasdaq and may be delisted as early as June 2025 if it does not regain compliance with listing requirements.
• The company is offering shares of common stock and pre-funded warrants in this offering.
• The company intends to use the net proceeds from this offering primarily to advance the clinical development of the combined companys research and development programs, to pay off certain of Decoys outstanding promissory notes as required thereby; and for other general corporate purposes, including working capital, research and development, and capital expenditures.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the merger presents potential opportunities, there are significant risks and uncertainties, including financial challenges and regulatory hurdles.

Positives

• The merger with Decoy Therapeutics provides Salarius stockholders with potential long-term value creation.
• The combined company will have a broader potential product portfolio and enhanced ability to raise capital.
• Decoy's expertise in peptide conjugates complements Salarius' small molecule assets, potentially addressing a wider range of diseases.
• The combined company plans to integrate Salarius assets, particularly the proprietary compound SP-3164, to expand its opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis targeting chimeras (PPROTACs).

Negatives

• Salarius has received a delisting notice from Nasdaq and may be delisted as early as June 2025 if it does not regain compliance with listing requirements.
• Salarius stockholders may experience dilution as a result of the merger and associated financing.
• The combined company may need to raise additional capital, which may cause further dilution or restrict operations.
• Decoy's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales and all of Decoy's product candidates are currently in the preclinical stage.

Risks

• The merger may be completed even if certain events occur that materially and adversely affect Salarius or Decoy.
• Salarius may not be able to effect the merger pursuant to the merger agreement, and failure to complete the merger could negatively impact Salarius stock price and the future business and financial results of Salarius.
• The market price of Salarius common stock following the merger may decline as a result of the merger.
• The combined company will need to raise additional capital by issuing securities or debt or through licensing or other strategic arrangements, which may cause dilution to the combined company's stockholders or restrict the combined company's operations or impact its proprietary rights.
• You will experience immediate and substantial dilution if you purchase Salarius securities in this offering.
• Substantial future sales or other issuances of Salarius common stock could depress the market for Salarius common stock.
• Salarius has broad discretion in how it uses the proceeds of this offering and may not use these proceeds effectively, which could affect Salarius results of operations and cause its common stock to decline.
• If the Merger is not completed, Salarius may not be able to otherwise source adequate liquidity to fund its operations, meet its obligations, and continue as a going concern.
• The pendency of the Merger could have an adverse effect on the trading price of Salarius common stock and its business, financial condition and prospects.
• Decoys financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales and all of Decoys product candidates are currently in the preclinical stage, and Decoy may continue to incur significant losses for the foreseeable future and never generate revenue from product sales.
• Because the approach Decoy is taking to discover and develop drugs is novel, it may never lead to marketable products.

Future Outlook

The combined company will focus on developing innovative peptide conjugates, leveraging Decoy's IMP 3 ACT platform and Salarius' SP-3164 compound, with an initial focus on infectious diseases and oncology.

Industry Context

The announcement reflects a trend of consolidation in the biotech industry, with companies seeking to diversify their pipelines and leverage synergies through mergers and acquisitions. The focus on peptide conjugates aligns with the growing interest in this therapeutic modality.

Comparison to Industry Standards

• The merger aims to create a company competitive in the peptide conjugate therapeutics market, similar to companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, ZepBound) who have seen success in diabetes and weight loss treatments.
• The combined company's approach to drug development, integrating Decoy's peptide conjugates with Salarius' small molecule assets, is similar to the strategy of companies developing antibody-drug conjugates (ADCs).
• The company's focus on P-PROTACs is in line with the industry's growing interest in targeted protein degradation as a therapeutic strategy, with companies like Arvinas and C4 Therapeutics leading the way.

Related Party Transactions

• Dr. McVicar, a member of the Salarius board of directors, serves as a consultant to DeuteRx and is a consultant to an affiliate of DeuteRx.
• On January 10, 2025, Salarius paid the Investor an aggregate amount in cash of $350,000 in exchange for the surrender and cancellation of the Warrant.

Stakeholder Impact

• Salarius stockholders may experience dilution as a result of the merger and associated financing.
• The combined company's success will depend on its ability to develop and commercialize new therapies, impacting patients with cancer and infectious diseases.
• Employees of both Salarius and Decoy may be affected by the integration of the two companies.

Next Steps

• Salarius intends to commence the Nasdaq initial listing process prior to the consummation of this offering and the Merger Closing.
• Following the Merger Closing, Salarius has also agreed to call a special stockholder meeting to approve, among other things, the conversion of the Series A Preferred Stock to be issued at the Merger Closing into shares of Salarius common stock.

Key Dates

Keywords

Merger, Decoy Therapeutics, Salarius Pharmaceuticals, S-1 Filing, Peptide Conjugates, SP-3164, SP-2577, Nasdaq, Qualified Financing, Reverse Asset Acquisition, P-PROTACs, Clinical Trials, Delisting Notice, Capital Raise